Wird geladen...
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
PURPOSE: Resistance to trastuzumab therapy is linked to phosphoinositol 3-kinase (PI3K) pathway activation. One key downstream effector and regulator of this pathway is the mechanistic target of rapamycin (mTOR). In 2011, a phase I/II study evaluated the combination of trastuzumab and everolimus (a...
Gespeichert in:
| Veröffentlicht in: | J Cancer Res Clin Oncol |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Springer Berlin Heidelberg
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5486569/ https://ncbi.nlm.nih.gov/pubmed/28247034 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-017-2358-x |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|